Grace Therapeutics, Inc. Market Cap ($28.47 Million)
Market Cap & Net Worth: Grace Therapeutics, Inc. (GRCE)
Grace Therapeutics, Inc. market cap. Grace Therapeutics, Inc. (NASDAQ:GRCE) has a market capitalization of $28.47 Million ($28.47 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23765 globally and #5162 in its home market, demonstrating a 1.66% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Grace Therapeutics, Inc.'s stock price $1.84 by its total outstanding shares 15474026 (15.47 Million). Also see cash flow conversion of Grace Therapeutics, Inc. for how efficiently the company converts equity into cash flow.
Grace Therapeutics, Inc. Market Cap History (2015–2026)
Grace Therapeutics, Inc. market cap history from 2015 to 2026. Data shows change from $1.89 Billion to $28.47 Million (-31.96% CAGR). Check today's stock price for Grace Therapeutics, Inc. for real-time trading data and today's change.
Index Memberships
Grace Therapeutics, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #670 of 976 |
Weight: Grace Therapeutics, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Grace Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Grace Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Grace Therapeutics, Inc. (GRCE) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
596.86x
Grace Therapeutics, Inc.'s market cap is 596.86 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.89 Billion | $216.29K | -$1.32 Million | 8756.94x | N/A |
| 2016 | $928.44 Million | $27.79K | -$4.66 Million | 33412.80x | N/A |
| 2021 | $116.98 Million | $196.00K | -$19.68 Million | 596.86x | N/A |
Competitor Companies of GRCE by Market Capitalization
Companies near Grace Therapeutics, Inc. in the global market cap rankings as of November 5, 2026. Also see Grace Therapeutics, Inc. assets under control for a full breakdown of the balance sheet.
Key companies related to Grace Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Grace Therapeutics, Inc. (2015–2026)
Market capitalization of Grace Therapeutics, Inc. from 2015 to today. Between 2015 and today, Grace Therapeutics, Inc.'s market cap moved from $1.89 Billion to $ 28.47 Million, with a yearly change of -31.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $28.47 Million | -46.82% |
| 2025 | $53.54 Million | -7.49% |
| 2024 | $57.87 Million | +29.41% |
| 2023 | $44.72 Million | -3.67% |
| 2022 | $46.42 Million | -60.32% |
| 2021 | $116.98 Million | -52.27% |
| 2020 | $245.11 Million | -86.53% |
| 2019 | $1.82 Billion | +195.18% |
| 2018 | $616.49 Million | -11.70% |
| 2017 | $698.19 Million | -24.80% |
| 2016 | $928.44 Million | -50.98% |
| 2015 | $1.89 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Grace Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $28.47 Million USD |
| MoneyControl | $28.47 Million USD |
| MarketWatch | $28.47 Million USD |
| marketcap.company | $28.47 Million USD |
| Reuters | $28.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a top… Read more